Tango Therapeutics Inc. (NASDAQ: TNGX) just delivered the kind of data that can reset a small‑cap oncology name, with shares soaring over 30% after new…
June 05, 2026
BioCardia’s Stock Surges on Clearer FDA Trial Path
BioCardia Inc. (NASDAQ: BCDA) is surging after the company said U.S. regulators have confirmed the trial pathway for its lead heart‑failure program. This latest move…
June 04, 2026
FDA Signals a Renewed Posture Toward Rare Disease
A recent meeting between acting FDA Commissioner Kyle Diamantas and senior executives from fifteen rare disease nonprofits offers a useful read on where the agency…
Biogen Inc., (NASDAQ: BIIB) is quietly strengthening its rare‑disease pipeline, with its investigational spinal muscular atrophy (SMA) therapy salanersen earning a coveted Breakthrough Therapy designation…
Iovance Biotherapeutics (NASDAQ: IOVA) is getting a welcome boost after Australia signed off on its flagship melanoma therapy, adding another pillar to the company’s global…
TG Therapeutics (NASDAQ: TGTX) is trading higher after fresh clinical data supported a more convenient, under‑the‑skin version of its multiple sclerosis therapy Briumvi (ublituximab‑xiiy), reinforcing…
Eli Lilly and Company (NYSE: LLY) announced that its targeted therapy Retevmo (selpercatinib) cut the risk of disease recurrence or death by 83 percent versus placebo in patients with…
Johnson & Johnson (NYSE: JNJ) has received FDA approval for a label expansion for TREMFYA (guselkumab), confirming it as the only IL‑23 inhibitor proven to…
BridgeBio Pharma (NASDAQ: BBIO) has received FDA acceptance and Priority Review for its investigational therapy BBP-418, which could become the first-ever approved treatment for limb-girdle…
Jupiter Neurosciences (NASDAQ: JUNS) has jumped back onto investor watchlists after announcing a term sheet for exclusive U.S. rights to ALA‑002, a next‑generation MDMA therapeutic,…
PharmAla Biotech’s (OTCQB: MDXXF) new licensing term sheet with Jupiter Neurosciences (NASDAQ: JUNS) gives Jupiter a differentiated MDMA‑based CNS asset while providing PharmAla with upfront…
May 19, 2026
Vertanical’s VER‑01 Wins FDA Breakthrough Nod in the Fight Against Chronic Low Back Pain
Vertanical’s experimental chronic pain drug VER‑01 just received a major boost from U.S. regulators: the FDA has granted it Breakthrough Therapy Designation as a first‑in‑class, non‑opioid treatment candidate for…